Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Clinical Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Bacteriology

Antimicrobial Susceptibilities ofHelicobacter pylori Isolates under Microaerophilic Atmospheres Established by Two Different Methods

Intetsu Kobayashi, Hiroe Muraoka, Takeshi Saika, Minoru Nishida, Toshio Fujioka, Masaru Nasu
Intetsu Kobayashi
Chemotherapy Division, Mitsubishi Kagaku Bio-Clinical Laboratories, Inc., Tokyo, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroe Muraoka
Chemotherapy Division, Mitsubishi Kagaku Bio-Clinical Laboratories, Inc., Tokyo, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takeshi Saika
Chemotherapy Division, Mitsubishi Kagaku Bio-Clinical Laboratories, Inc., Tokyo, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Minoru Nishida
Chemotherapy Division, Mitsubishi Kagaku Bio-Clinical Laboratories, Inc., Tokyo, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshio Fujioka
Second Department of Internal Medicine, Oita Medical University, Oita, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masaru Nasu
Second Department of Internal Medicine, Oita Medical University, Oita, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JCM.39.7.2646-2647.2001
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The MICs of clarithromycin, amoxicillin, and metronidazole for 150Helicobacter pylori isolates were determined using the AnaeroPack system and were compared with those determined using a microaerophilic incubator. The MICs of clarithromycin, amoxicillin, and metronidazole determined under both microaerophilic atmospheres were mostly within one twofold dilution for 146 (97.3%), 150 (100%), and 149 (99.3%) of the isolates, respectively.

Helicobacter pylori is the major causative pathogen of active chronic gastritis and peptic ulcers (6, 13), and infection with H. pylori is associated with an increased risk of developing gastric cancer (10). The National Institutes of Health (Bethesda, Md.) have subsequently recommended the routine treatment of patients withH. pylori infection with antibiotics to eradicate the causative pathogen (9). Clarithromycin and metronidazole are representative antibiotics which are used to eradicate H. pylori (2, 4). However, for some patients antibacterial therapy fails to eradicate the pathogen because of the frequent development of resistance to clarithromycin and metronidazole (11), and this may lead to relapse or recurrent infection. Testing for the susceptibility of H. pylori isolates to these antibiotics is the first step to successful therapy for patients with H. pylori infections. MICs of test antibiotics forH. pylori are determined by the agar dilution method according to the guidelines established by the National Committee for Clinical Laboratory Standards (NCCLS) (7). Since H. pylori is fastidious and slow-growing, for MIC determination it takes 3 to 4 days at 35°C for visible colonies to form in rich culture medium under a microaerophilic atmosphere. However, very few clinical microbiology laboratories are equipped with a microaerophilic incubator. For the present study, a small jar enclosed with a recently developed microaerophilic gas-generating system (AnaeroPack; Mitsubishi Gas Chemical Co., Inc., Tokyo, Japan) was tested for MIC determination of antibiotics for H. pylori. The AnaeroPack can generate CO2 by simply the cutting of one end of the gas pack. The manufacturer's instructions show that after 24 h of incubation the AnaeroPack can produce a suitable atmosphere for the growth of H. pylori (O2, 4.7%; CO2, 9.2%) in a closed jar. For the present study, the MICs of clarithromycin, amoxicillin, and metronidazole for 150 H. pylori isolates were determined using the AnaeroPack and were compared with those determined with a conventional microaerophilic incubator (Tabai Espec Co., Osaka, Japan). One hundred fifty strains ofH. pylori were isolated from gastric biopsy specimens from patients with gastritis or peptic ulcers in 1999. After the specimens were cultured using selective agar medium as described previously (12), the isolates were stored at −80°C in brucella broth (Difco Laboratories, Detroit, Mich.) containing 10% dimethyl sulfoxide and 10% horse serum until use. The susceptibility ofH. pylori isolates to the three antibiotics was determined under the microaerophilic atmospheres established by the two different methods. The results were expressed as the MICs at which 50% of the isolates were inhibited (MIC50s), the MIC90s, and the MIC ranges of three antibiotics for 150 isolates.

The MIC50s, MIC90s, and MIC ranges of clarithromycin for the 150 H. pylori isolates were equivalent between the two microaerophilic atmospheres (Table1). Similar results were obtained for the MIC50s, MIC90s, and MIC ranges of amoxicillin and metronidazole in both culture atmospheres. Table 2shows the correlation between the individual MICs of clarithromycin for the H. pylori isolates obtained under microaerophilic atmospheres generated by the two different methods. The MICs of clarithromycin determined by both methods were the same for 99 (66.0%) of the 150 isolates, but those for 35 (23.3%) and 3 (2.0%) isolates were one and two twofold dilutions lower, respectively, when isolates were grown in the AnaeroPack than when they were grown in the incubator. In contrast, the MICs of clarithromycin for 12 (8.0%) and 1 (0.7%) isolate were one and two twofold dilutions higher when isolates were grown in the AnaeroPack than when isolates were grown in the incubator. However, the MICs of clarithromycin for 47 (31.3%) of the 150 isolates only differed by one twofold dilution between the two systems. In general, there was a close correlation between the MICs of clarithromycin for H. pylori isolates determined under microaerophilic atmospheres established by the two different methods. The same MICs of amoxicillin were obtained in both groups for 127 (84.7%) of the 150 isolates, but those for 19 (12.7%) and 4 (2.7%) isolates were within one twofold dilution higher and lower, respectively, when isolates were grown in the AnaeroPack than when they were grown in the incubator. No isolates showed a difference in amoxicillin MICs of more than one twofold dilution in either group. For metronidazole, the same MICs were obtained for 111 (74.0%) of the 150 isolates by the two methods, but the MICs for 33 (22.0%) and 1 (0.7%) isolate were one and two twofold dilutions higher, respectively, when the isolates were grown in the AnaeroPack. In contrast, the MICs for 5 (3.3%) isolates grown in the AnaeroPack were lower than those for isolates grown in the incubator.

View this table:
  • View inline
  • View popup
Table 1.

Susceptibility of 150 H. pylori isolates to clarithromycin, amoxicillin, and metronidazole determined under microaerophilic atmospheres established by two different methods

View this table:
  • View inline
  • View popup
Table 2.

Correlation between MICs of clarithromycin, amoxicillin, and metronidazole for 150 H. pylori isolates determined under microaerophilic atmospheres established by two different methods

As mentioned above, H. pylori is a fastidious organism which only grows under microaerophilic atmospheres. According to theClinical Microbiology Procedures Handbook (3), an atmosphere of 10% CO2, 5% O2, and 85% N2 is necessary to culture H. pylori, like that for Campylobacter spp. Various types of microaerophilic systems, including microaerophilic incubators and gas-generating systems, have been used to generate these conditions. The former require high-cost laboratory equipment, with gas tanks which also require high maintenance, but can produce and control an appropriate atmosphere for bacterial growth. The latter include several gas-generating systems which are now available, but some of these systems cannot produce a sufficient microaerophilic atmosphere for the optimal growth of some microaerophilic bacteria because of an insufficient supply of each gas at the required pressure. However, macrolide antibiotics such as clarithromycin are inactivated by long incubation in a high CO2 atmosphere, and as a result, the MICs of macrolides for H. pylori isolates often become higher (1, 5). In the guidelines established by the NCCLS (8), the MIC interpretive standard of clarithromycin forH. pylori is defined as follows: sensitive, ≤0.25 μg/ml; intermediate, 0.5 μg/ml; and resistant, ≥ 1 μg/ml. When a MIC is estimated to be two twofold dilutions greater than the real value on the basis of the interpretive standard, the susceptibility of H. pylori to clarithromycin changes from sensitive to resistant. Therefore, the control of the precise conditions is important for the susceptibility testing of H. pylori.

The MICs of clarithromycin for 150 H. pylori isolates under microaerophilic atmospheres established by using the microaerophilic incubator corresponded well to those under atmospheres established by using the AnaeroPack.

In conclusion, the AnaeroPack was a convenient and easy way to produce a microaerophilic atmosphere that met the guidelines established by the NCCLS and resulted in appropriate conditions for the growth of H. pylori. The AnaeroPack was successfully used for the determination of the MICs of clarithromycin, amoxicillin, and metronidazole forH. pylori isolates.

FOOTNOTES

    • Received 16 October 2000.
    • Returned for modification 24 January 2001.
    • Accepted 24 April 2001.
  • Copyright © 2001 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Debets-Ossenkopp Y. J.,
    2. Namavar F.,
    3. MacLaren D. M.
    Effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents.Eur. J. Clin. Microbiol. Infect. Dis.141993353355
    OpenUrl
  2. 2.↵
    European Helicobacter pylori Study Group Current European concepts in the management of Helicobacter pylori infection.Gut411997813
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Grasmick A.
    Processing and interpretation of bacterial fecal cultures Clinical microbiology procedures handbook. Isenberg H. D. 1994 1.10.1 1.10.25 American Society for Microbiology Washington, D.C.
  4. 4.↵
    1. Lind T.,
    2. van Zanten S. V.,
    3. Unge P.,
    4. Spiller R.,
    5. Bayerdorffer E.,
    6. O'Morain C.,
    7. Bardhan K. D.,
    8. Bradette M.,
    9. Chiba N.,
    10. Wrangstadh M.,
    11. Cederberg C.,
    12. Idstrom J. P.
    Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH1 study.Helicobacter31996138144
    OpenUrl
  5. 5.↵
    1. Malanoski G. J.,
    2. Eliopoulos G. M.,
    3. Ferraro M. J.,
    4. Moellerring R. C.
    Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin.Eur. J. Clin. Microbiol. Infect. Dis.121993131133
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Martin J. B.
    Helicobacter pylori and the pathogenesis of gastroduodenal inflammation.J. Infect. Dis.1611990626633
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, fifth ed. NCCLS document M7–A5. 2000 National Committee for Clinical Laboratory Standards Wayne, Pa
  8. 8.↵
    National Committee for Clinical Laboratory Standards Performance standards for antimicrobial susceptibility testing. Tenth informational supplement (aerobic dilution) M100–S10. 2000 National Committee for Clinical Laboratory Standards Wayne, Pa
  9. 9.↵
    National Institutes of Health NIH consensus development panel on Helicobacter pylori in peptic ulcer disease: Helicobacter pylori in peptic ulcer disease.JAMA27219946569
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Parsonnet J.,
    2. Friedman G. D.,
    3. Vandensteen D. P.,
    4. Chang Y.,
    5. Vogelman J. H.,
    6. Orentreich N.,
    7. Sibley R. K.
    Helicobacter pylori infection and the risk of gastric carcinoma.N. Engl. J. Med.325199111271131
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Sorberg M.,
    2. Hanberger H.,
    3. Nilsson M.,
    4. Bjorkman A.,
    5. Nilsson L. E.
    Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori.Antimicrob. Agents Chemother.42199812221228
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Suzuki J.,
    2. Muraoka H.,
    3. Kobayashi I.,
    4. Fujita T.,
    5. Mine T.
    Rare incidence of interspousal transmission of Helicobacter pylori in asymptomatic individuals in Japan.J. Clin. Microbiol.37199941744176
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Warren J. R.,
    2. Marshall B. J.
    Unidentified curved bacilli on gastric epithelium in active chronic gastritis.Lancetii198312731275
    OpenUrl
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Antimicrobial Susceptibilities ofHelicobacter pylori Isolates under Microaerophilic Atmospheres Established by Two Different Methods
Intetsu Kobayashi, Hiroe Muraoka, Takeshi Saika, Minoru Nishida, Toshio Fujioka, Masaru Nasu
Journal of Clinical Microbiology Jul 2001, 39 (7) 2646-2647; DOI: 10.1128/JCM.39.7.2646-2647.2001

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Clinical Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Antimicrobial Susceptibilities ofHelicobacter pylori Isolates under Microaerophilic Atmospheres Established by Two Different Methods
(Your Name) has forwarded a page to you from Journal of Clinical Microbiology
(Your Name) thought you would be interested in this article in Journal of Clinical Microbiology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Antimicrobial Susceptibilities ofHelicobacter pylori Isolates under Microaerophilic Atmospheres Established by Two Different Methods
Intetsu Kobayashi, Hiroe Muraoka, Takeshi Saika, Minoru Nishida, Toshio Fujioka, Masaru Nasu
Journal of Clinical Microbiology Jul 2001, 39 (7) 2646-2647; DOI: 10.1128/JCM.39.7.2646-2647.2001
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
Helicobacter pylori

Related Articles

Cited By...

About

  • About JCM
  • Editor in Chief
  • Board of Editors
  • Editor Conflicts of Interest
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Resources for Clinical Microbiologists
  • Ethics
  • Contact Us

Follow #JClinMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

 

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0095-1137; Online ISSN: 1098-660X